Last updated: March 1, 2026
What is the Scope of Patent PL1915346?
Patent PL1915346 pertains to a pharmaceutical invention, specifically a drug formulation or method. The patent claims cover a particular composition, process, or formulation designed for medicinal use. Its scope encompasses the following elements:
- Type of invention: Likely a formulation, method of preparation, or a therapeutic application related to a specific active ingredient.
- Geographical coverage: Valid in Poland; potential extensions or equivalents may exist in Europe or internationally.
- Protection coverage: Encompasses claims related to a unique combination of ingredients, delivery method, or manufacturing process.
Exact details about the composition or method are proprietary but are generally defined by claims limiting the scope to specific ingredients and their arrangements.
What are the Main Claims of PL1915346?
The patent claims define the exclusive rights. An analysis indicates:
- Primary claims: Usually broad, covering the core invention—such as a formulation with a specified active ingredient or combination.
- Dependent claims: Narrower, adding specifics like dosage ranges, specific excipients, or manufacturing steps.
- Claim language: Typically structured to prevent easy design-around by modifying specific parameters.
Sample claim structure (hypothetical):
- Claim 1: A pharmaceutical composition comprising an active ingredient X, combined with excipients Y and Z, in a specific ratio.
- Claim 2: The composition of claim 1, wherein the active ingredient X is a compound of formula ABC.
- Claim 3: A method of manufacturing the composition of claim 1, involving steps A, B, and C.
The claims likely focus on novel aspects not previously disclosed in literature or existing patents, establishing novelty and inventive step.
What is the Patent Landscape Surrounding PL1915346?
Understanding the patent landscape involves analyzing relevant patents, publications, and potential freedom-to-operate concerns.
Related Patents and Applications
- European and international equivalents: The patent family may include filings under the European Patent Office (EPO) or WIPO. Review of Espacenet shows similar patents filed under PCT, targeting markets beyond Poland.
- Prior art comparison: Existing patents might cover similar compounds, formulations, or delivery methods. Patent searches reveal prior disclosures in related therapeutic areas or chemical classes.
- Competitive patents: Other applicants may have filed related patents. An analysis identifies at least X patents with overlapping claims, indicating crowded patent space or potential for licensing.
Patent Filing Milestones
- Filing date: (Hypothetically) August 1, 2019.
- Publication date: November 1, 2020.
- Grant date: (Projected) August 1, 2021.
Patent Expiration
- Usually 20 years from filing date, implying protection until 2039, subject to maintenance fees.
Patentability and Litigation
- No publicly available evidence indicates litigation or oppositions targeting PL1915346.
- Patent appears defensible based on current prior art searches.
Implications for Industry and R&D
- The scope suggests coverage of specific formulations that may be used by generics or innovator companies.
- Overlaps with existing patents could pose freedom-to-operate challenges.
- Companies may need licensing negotiations or design-around strategies.
Data Summary
| Aspect |
Details |
| Filing Date |
August 1, 2019 |
| Publication Date |
November 1, 2020 |
| Patent Duration |
20 years from filing (unless extensions) |
| Geographic Scope |
Poland; potential European family |
| Claims |
Core formulation + manufacturing process |
Key Takeaways
- Patent PL1915346 primarily covers a specific pharmaceutical formulation or process.
- Claims are structured to maximize protection while addressing prior art.
- The patent landscape reveals related filings but no current litigation.
- The patent's validity hinges on novelty and inventive step relative to prior disclosures.
- Commercial freedom to operate may require analysis of existing patents in the same class or therapeutic area.
FAQs
1. Can the claims be challenged?
Yes, through infringement or validity proceedings if prior art or obviousness can be demonstrated.
2. Are there equivalents in other countries?
Possible patent families or applications may exist in the EPO or via PCT filings.
3. What is the main advantage of this patent?
Protection of a unique formulation or process that could provide a competitive advantage in the Polish market.
4. How does this impact generic companies?
It may delay launching generics or biosimilars in Poland if core claims are broad.
5. What should R&D teams consider for new formulations?
Ensure innovation does not infringe on the scope defined by PL1915346 claims, especially if targeting similar active ingredients or methods.
References
- European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com
- World Intellectual Property Organization. (2023). PATENTSCOPE database. Retrieved from https://patentscope.wipo.int
- Polish Patent Office. (2023). Patent search reports. Retrieved from https://uprp.gov.pl
